NEW YORK (GenomeWeb) – Although it has been known for over a decade that two subtypes of diffuse large B-cell lymphoma (DLBCL), a form of non-Hodgkin lymphoma, have different prognoses and may respond differently to targeted treatment, routinely distinguishing between them has proved challenging.

Now, a team of researchers in France has developed an inexpensive classification method using a panel of 14 gene signatures and garden-variety lab equipment that may provide competition for commercial products being developed as companion diagnostics.